Literature DB >> 24783001

Oxidative stress in graves' disease.

Claudio Marcocci1, Marenza Leo1, Maria Antonietta Altea1.   

Abstract

Increased reactive oxygen species (ROS) generation and the consequent oxidative damage are involved in the development of several diseases, including autoimmune diseases. Graves' disease is an autoimmune disorder characterized by hyperthyroidism and, less frequently, orbitopathy. Hyperthyroidism is characterized by increased oxidative stress. Untreated hyperthyroidism is associated with an increase of several parameters of oxidative stress and in most studies (but not all) by an increase of antioxidant defense enzymes. Restoration of euthyroidism with antithyroid drug is associated with a reversal of the biochemical abnormalities associated with oxidative stress. Animal and human studies suggest that increased ROS may directly contribute to some clinical manifestation of the disease, including orbitopathy. Antioxidants administered alone improve some clinical signs and symptoms of hyperthyroidism and, when associated with antithyroid drugs, induce a more rapid control of clinical manifestations and a faster achievement of euthyroidism. A large randomized clinical trial has shown that antioxidant supplementation (selenium) may also be beneficial for mild Graves' orbitopathy.

Entities:  

Keywords:  Antithyroid drugs; Graves' orbitopathy; Hyperthyroidism; Selenium

Year:  2012        PMID: 24783001      PMCID: PMC3821469          DOI: 10.1159/000337976

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN: 2235-0640


  43 in total

1.  Effects of pulse methylprednisolone and oral methylprednisolone treatments on serum levels of oxidative stress markers in Graves' ophthalmopathy.

Authors:  Ersin Akarsu; Hakan Buyukhatipoglu; Sebnem Aktaran; Naciye Kurtul
Journal:  Clin Endocrinol (Oxf)       Date:  2011-01       Impact factor: 3.478

2.  Oxygen free radicals in interleukin-1beta-induced glycosaminoglycan production by retro-ocular fibroblasts from normal subjects and Graves' ophthalmopathy patients.

Authors:  R Lu; P Wang; L Wartofsky; B D Sutton; J L Zweier; R S Bahn; J Garrity; K D Burman
Journal:  Thyroid       Date:  1999-03       Impact factor: 6.568

3.  Antioxidant status in experimental hyperthyroidism: effect of vitamin E supplementation.

Authors:  A Seven; O Seymen; S Hatemi; H Hatemi; G Yiğit; G Candan
Journal:  Clin Chim Acta       Date:  1996-12-09       Impact factor: 3.786

4.  Vitamin E protects against thyroxine-induced acceleration of lipid peroxidation in cardiac and skeletal muscles in rats.

Authors:  K Asayama; K Dobashi; H Hayashibe; K Kato
Journal:  J Nutr Sci Vitaminol (Tokyo)       Date:  1989-10       Impact factor: 2.000

5.  Increased oxidative DNA damage, lipid peroxidation, and reactive oxygen species in cultured orbital fibroblasts from patients with Graves' ophthalmopathy: evidence that oxidative stress has a role in this disorder.

Authors:  C-C Tsai; S-B Wu; C-Y Cheng; S-C Kao; H-C Kau; S-H Chiou; W-M Hsu; Y-H Wei
Journal:  Eye (Lond)       Date:  2010-03-19       Impact factor: 3.775

6.  Free radicals and Graves' disease: the effects of therapy.

Authors:  R Wilson; M Chopra; H Bradley; J H McKillop; W E Smith; J A Thomson
Journal:  Clin Endocrinol (Oxf)       Date:  1989-04       Impact factor: 3.478

Review 7.  Roles of hydrogen peroxide in thyroid physiology and disease.

Authors:  Y Song; N Driessens; M Costa; X De Deken; V Detours; B Corvilain; C Maenhaut; F Miot; J Van Sande; M-C Many; J E Dumont
Journal:  J Clin Endocrinol Metab       Date:  2007-07-31       Impact factor: 5.958

8.  Supplementation with antioxidants in the treatment of Graves' disease; the effect on glutathione peroxidase activity and concentration of selenium.

Authors:  Vesna Bacic Vrca; Franjo Skreb; Ivana Cepelak; Zeljko Romic; Ljiljana Mayer
Journal:  Clin Chim Acta       Date:  2004-03       Impact factor: 3.786

9.  Activity of antioxidative enzymes and concentration of malondialdehyde as oxidative status markers in women with newly diagnosed Graves-Basedow disease and after thiamazole therapy leading to euthyroidism.

Authors:  Barbara Rybus-Kalinowska; Krystyna Zwirska-Korczala; Mariusz Kalinowski; Michał Kukla; Ewa Birkner; Jerzy Jochem
Journal:  Pol Arch Med Wewn       Date:  2008 Jul-Aug

10.  Levels of malondialdehyde and superoxide dismutase in subclinical hyperthyroidism.

Authors:  Ali Cetinkaya; Ergul Belge Kurutas; Mehmet Akif Buyukbese; Bulent Kantarceken; Ertan Bulbuloglu
Journal:  Mediators Inflamm       Date:  2005-02-24       Impact factor: 4.711

View more
  31 in total

1.  Oxidative Stress, Nuclear Factor-κB Pathway and Current Smoking in Graves' Ophthalmopathy.

Authors:  Horea Ioan Ursu; Monica Livia Gheorghiu
Journal:  Eur Thyroid J       Date:  2013-02-21

2.  Stimulatory TSH-Receptor Antibodies and Oxidative Stress in Graves Disease.

Authors:  Tanja Diana; Andreas Daiber; Matthias Oelze; Susanne Neumann; Paul D Olivo; Michael Kanitz; Paul Stamm; George J Kahaly
Journal:  J Clin Endocrinol Metab       Date:  2018-10-01       Impact factor: 5.958

3.  A 2016 Italian Survey about the Clinical Use of Selenium in Thyroid Disease.

Authors:  Roberto Negro; Roberto Attanasio; Franco Grimaldi; Claudio Marcocci; Rinaldo Guglielmi; Enrico Papini
Journal:  Eur Thyroid J       Date:  2016-08-06

4.  Oxidative Stress in Graves Disease and Graves Orbitopathy.

Authors:  Giulia Lanzolla; Claudio Marcocci; Michele Marinò
Journal:  Eur Thyroid J       Date:  2020-11-20

5.  Systemic oxidative stress to nucleic acids is unaltered following radioiodine therapy of patients with benign nodular goiter.

Authors:  Steen J Bonnema; Elisabeth S Stovgaard; Søren Fast; Kasper Broedbaek; Jon T Andersen; Allan Weimann; Peter Grupe; Laszlo Hegedüs; Henrik E Poulsen
Journal:  Eur Thyroid J       Date:  2015-02-11

6.  Evaluation of Serum S100A8/S100A9 Levels in Patients with Autoimmune Thyroid Diseases.

Authors:  Hakan Korkmaz; Suzan Tabur; Esen Savaş; Mesut Özkaya; Şefika Nur Aksoy; Nurten Aksoy; Ersin Akarsu
Journal:  Balkan Med J       Date:  2016-09-01       Impact factor: 2.021

7.  Paraoxonase and arylesterase levels in autoimmune thyroid diseases.

Authors:  Hakan Korkmaz; Suzan Tabur; Mesut Ozkaya; Elif Oguz; Umut Elboga; Nurten Aksoy; Ersin Akarsu
Journal:  Redox Rep       Date:  2016-01-21       Impact factor: 4.412

8.  Lipid peroxidation, proteins modifications, anti-oxidant enzymes activities and selenium deficiency in the plasma of hashitoxicosis patients.

Authors:  Malek Mseddi; Riadh Ben Mansour; Fatma Mnif; Bochra Gargouri; Mohamed Abid; Fadhel Guermazi; Hamadi Attia; Saloua Lassoued
Journal:  Ther Adv Endocrinol Metab       Date:  2015-10       Impact factor: 3.565

9.  A 2018 European Thyroid Association Survey on the Use of Selenium Supplementation in Graves' Hyperthyroidism and Graves' Orbitopathy.

Authors:  Roberto Negro; Laszlo Hegedüs; Roberto Attanasio; Enrico Papini; Kristian H Winther
Journal:  Eur Thyroid J       Date:  2018-12-13

10.  THE EFFECT OF ANTITHYROID DRUGS ON OSTEOPONTIN AND OXIDATIVE STRESS IN GRAVES' DISEASE.

Authors:  M Kocak; E Akarsu; H Korkmaz; S Taysi
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Apr-Jun       Impact factor: 0.877

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.